The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses
Helen Campbell(University of Oxford), Mark Sculpher(University of York), Andrea Manca(University of Sassari), Judith M. Bliss(Institute of Cancer Research), David Cameron(Corewell Health), Penelope Hopwood, Alastair Gray(University of Oxford), Janet Dunn(National Health Service), L. Johnson(Michigan State University), David Bloomfield(Royal Sussex County Hospital), Peter Ellis(Oldham Council), David Epstein(Universidad de Granada), Adrian L. Harris(University of Oxford), Helena Earl(University of Cambridge), Louise Hiller(University of Warwick), Christopher Poole(Guy's Hospital), Peter Barrett‐Lee(Velindre Cancer Centre), J. Yarnold(Royal Marsden NHS Foundation Trust), Susan Griffin(University of York)
Cited by 46
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
High burden and pervasive positive selection of somatic mutations in normal human skin
|Science|2015|1.8k